Oscar Andrade, MD
Family Medicine · Globe, AZNPI 1275685521
Payments from drug & device makers
Across 171 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$511
- AbbVie$510
- Novo Nordisk$369
- Lilly USA, LLC$282
- Novartis$132
- AstraZeneca$131
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,93799%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $511 |
| AbbVie(2 entities) | 32 | $510 |
| Novo Nordisk | 14 | $369 |
| Lilly USA, LLC | 18 | $282 |
| Novartis | 7 | $132 |
| AstraZeneca | 9 | $131 |
| Pfizer | 8 | $127 |
| Johnson & Johnson | 8 | $119 |
| Organogenesis Inc. | 5 | $108 |
| Mimedx Group, Inc. | 4 | $78 |
| Amgen | 4 | $76 |
| Lucid Diagnostics Inc. | 4 | $62 |
| Organon | 4 | $53 |
| Merck | 3 | $45 |
| Exact Sciences | 2 | $45 |
| GSK | 3 | $44 |
| Edwards Lifesciences | 2 | $42 |
| Tactile Systems Technology Inc | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Bayer | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Dexcom, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Electromed, Inc. | 2 | $14 |
| Urgo Medical North America, LLC | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
How this compares
$2,967 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $81,373 |
| OzempicSemaglutide | 34 | $33,273 |
| TrulicityDulaglutide | 18 | $22,675 |
| EliquisApixaban | 23 | $18,728 |
| FarxigaDapagliflozin Propanediol | 27 | $16,873 |
| MounjaroTirzepatide | 16 | $16,720 |
| XareltoRivaroxaban | 18 | $15,050 |
| QuliptaAtogepant | 13 | $14,567 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $13,445 |
| JanuviaSitagliptin Phosphate | 15 | $12,731 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $10,077 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,931 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,166 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,848 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $511 | $94,818102 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $282 | $39,39534 claims |
| Novo NordiskOzempic | $369 | $33,27334 claims |
| AstraZenecaFarxiga, Symbicort | $131 | $21,72145 claims |
| PfizerEliquis | $127 | $18,72823 claims |
| Johnson & JohnsonXarelto | $119 | $15,05018 claims |
| AbbVieQulipta | $510 | $14,56713 claims |
| MerckJanuvia | $45 | $12,73115 claims |
| GSKAnoro Ellipta, Breo Ellipta | $44 | $12,09628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Globe
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.